



# **LIFE SCIENCES ENTREPRENEURS ACCELERATION PROGRAM**



# LIFE SCIENCES

## ENTREPRENEURS ACCELERATION PROGRAM

### FUELING YOUR MISSION

**“As a start-up, careful management of resources and selection of key partners are critical to advancing company goals. McDermott met every criteria I needed to successfully bring an FDA approved artificial intelligence medical device to market.”**

*– R.A. Bavasso CEO, nQ Medical-Inc.*

To help qualifying entrepreneurs and young companies achieve their mission and avoid costly mistakes, McDermott created the Life Sciences Entrepreneurs Acceleration Program (LEAP). **We provide these organizations with high-quality legal services during the earliest stages of corporate life through engagement, plus incentives in the form of deferred fees, discounts, fixed-fee arrangements and awards.**

---

## Top Honors For Health and Life Sciences

*Legal 500 USA*

## Nationally Ranked Life Sciences Practice

*Chambers USA*

---

We understand that early stage life sciences clients need legal advice in such complex areas as corporate formation, financing, intellectual property, licensing and collaborations, data privacy and cybersecurity, and employee benefits. Our Life Sciences Industry Group has a deep bench of lawyers who are highly regarded in these complex areas of law. Our corporate lawyers have demonstrated success in advising life sciences companies on the full range of transactional legal needs, and our intellectual property lawyers are renowned for protecting the IP rights of our clients both in and out of court. McDermott is also a pioneer in the field of employee benefits and advises life sciences companies on various compensation strategies to both secure and maintain leadership.



## LEAP CLIENTS PAST AND PRESENT



Biopharmaceutical company committed to the early detection, diagnosis and treatment of serious diseases based on its patented Z-TECT™ technology platform, which provides high sensitivity detection and accurate quantification of biomolecules down to the zeptomole range.

AKRIVIS TECHNOLOGIES

Applied Therapeutics Inc.

Therapeutic company developing novel small molecule therapeutics for metabolic and cardiovascular diseases.

APPLIED THERAPEUTICS INC.



Developed a novel methodology for the rapid detection of foodborne pathogens. The technology is compatible with an automated and data driven approach to food safety, but can also be effectively deployed in low resource environments.

BIOINSIGHT



French based company developing advanced 3D modeling and 3D printing to fabricate life-like artificial organs for medical training and pre-operative planning in the clinical and surgical settings.

BIOMODEX



Medical device company with a platform technology that uses a metal alloy to produce targeted ablation.

CANDESANT BIOMEDICAL



Early-stage company developing cell culture methods that enable tumor cells taken from a human tumor biopsy to be cultured so that they largely retain the genotypic, proteomic and phenotypic profile of their parent tumor cell type.

CELLARIA BIOSCIENCES



CustodyRx merges Blockchain driven cloud software with IoT, and RFID sensor technology to solve Chain of Custody and Inventory Management challenges for the health care and pharmaceutical industries.

HEALTHCARE/PHARMA SOFTWARE



Biotechnology start-up developing a new technology to predict and monitor response to Immuno-Oncology therapy.

CYTOSITE



Engine Biosciences' artificial intelligence and genetic perturbation platform allows researchers and drug developers to uncover the gene interactions and biological networks underlying diseases faster and more cost-effectively.

ENGINE BIOSCIENCES



Formed to leverage FLECS Technology to provide drug-makers and researchers direct access to cellular force generation at the single-cell level – a cellular behavior that was previously inaccessible in an automated way.

FORCYTE



Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company is engaged in the development of a non-invasive approach.

GLYSCEND













Implicity is a medical device software company that provides a cloud platform for remote monitoring of patients implanted with connected medical devices (pacemakers/defibrillators).

IMPLICITY







## COMPREHENSIVE SERVICES

- Intellectual Property
- Licensing & Partnering
- Mergers & Acquisitions
- Venture Capital
- Public Offerings
- Royalty Stream Financing
- Privacy & Cybersecurity

## LEAP CLIENTS PAST AND PRESENT

 <p>Clinical stage pharmaceutical company developing small molecules with a unique mechanism of action for the treatment of Alzheimer's disease which targets ER protein processing and pathways.</p> <p><b>JACE BIOMEDICAL INC.</b></p>	 <p>New development-stage privately held company focused on developing Promitil® - Pegylated Liposomal Mitomycin-C Prodrug (PL-MLP) – an innovative agent for targets cancer therapy.</p> <p><b>LIPOMEDIX</b></p>	 <p>Clinical development company dedicated to the development and commercialization of life-saving molecularly targeted therapeutics for the treatment of multi-drug resistant cancers with a special emphasis on women's oncology.</p> <p><b>NEMUCORE MEDICAL INNOVATIONS, INC.</b></p>	 <p>A de-risking technology provider pioneering in silico clinical trials. The company's mission is to establish in silico as the third pillar of drug R&amp;D in support of in vitro and in vivo explorations.</p> <p><b>NOVADISCOVERY</b></p>	 <p>AI company that has developed a computational biomarker that has been proven in clinical trials to substantially change the way neuromotor, neurocognitive, and neurobehavioral disorders are managed.</p> <p><b>NQ MEDICAL</b></p>
 <p>Peach IntelliHealth is a NY based company using AI &amp; machine learning in healthcare. Their mission is to improve healthcare outcomes through actionable data analytics.</p> <p><b>PEACH INTELLIHEALTH</b></p>	 <p>Biotechnology company developing targeting nanoparticle based light therapies for diseases for which there are currently no effective treatments or for which current treatments do not perform ideally for patients.</p> <p><b>POPBIOTECH</b></p>	 <p>Prapela is an infant sleep tech company focused on the integration of stochastic resonance technology into medical and consumer products to help newborns breathe and relax.</p> <p><b>PRAPELA</b></p>	 <p>Early-stage company providing state of the art protein characterization to ensure viability and stability of protein products for the biopharmaceutical and biotechnology industries.</p> <p><b>PROTEIN DYNAMIC SOLUTIONS</b></p>	 <p>Medical device company developing and commercializing high-quality, cost-effective products for non-invasive, dynamic assessments of blood flow and vascular status.</p> <p><b>VASOPTIC MEDICAL INC.</b></p>

## LEAP COMMITTEE

	<p><b>Jason B. Caron</b> Partner Washington, DC jcaron@mwe.com +1 202 756 8243</p>		<p><b>Byron S. Kalogerou</b> Partner Boston bkalogerou@mwe.com +1 617 535 4441</p>		<p><b>Mark J. Mihanovic</b> Partner Silicon Valley Los Angeles mmihanovic@mwe.com +1 650 815 7438</p>
	<p><b>Judy Mohr, PhD</b> Partner Silicon Valley jmohr@mwe.com +1 650 815 7630</p>		<p><b>Richard B. Smith</b> Partner Boston rbsmith@mwe.com +1 617 535 3876</p>		<p><b>Kristian A. Werling</b> Partner Chicago kwerling@mwe.com +1 312 984 2157</p>

## ABOUT THE ACTIVE CLIENTS

---



BioInsight has developed a novel methodology for the rapid detection of foodborne pathogens, including *E. coli*, Listeria and Salmonella. This cost-effective 15-minute test combines ease of use with a high degree of sensitivity and specificity. The technology is compatible with an automated and data driven approach to food safety, but can also be effectively deployed in low resource environments. BioInsight is based in Cambridge, MA.

### CONTACT

Nick Microulis  
Co-Founder & CEO  
+1 917 572 0824

## CustodyRx

CustodyRx merges Blockchain driven cloud software with IoT, and RFID sensor technology to solve Chain of Custody and Inventory Management challenges for the healthcare and pharmaceutical industries, including hospitals, and emergency medical services providers (EMT's and ambulances).

### CONTACT

Robert Zanghi  
Founder  
+1 617 694 7174  
McDermott Partner:  
Jed Gordon



Forcyte Biotechnologies, Inc. was formed to leverage FLECS Technology (originally developed in the Di Carlo Lab @ UCLA) to provide drug-makers and researchers direct access to cellular force generation at the single-cell level—a cellular behavior that was previously inaccessible in an automated way. We provide a fundamentally new class of cell-based assays that functionally evaluate single-cell contractility, integrated into standard multi-wellplate vessels—available both as end-to-end services, and as consumables.

### CONTACT

Ivan Pushkarsky  
President & Founder  
McDermott Partner:  
Roger Kuan

## glyscend

Glyscend is dedicated to the development of a truly revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia.

### CONTACT

Ashish Nimgaonkar, MD  
Chief Executive Officer



Novadiscovery is a de-risking technology provider pioneering in silico clinical trials. The company's mission is to establish in silico as the third pillar of drug R&D in support of in vitro and in vivo explorations. Nova helps its biotech and pharma partners unlock the potential of modeling and simulation to de-risk the discovery and development of new therapies. The company's Whitebox In Silico Engine (WISE) increases probability of success while reducing time and costs. The team combines biology, drug development, mathematics, software development and machine learning expertise.

### CONTACT

François-Henri Boisse  
Chief Executive Officer  
McDermott Partner:  
Jennifer Bock



nQ Medical is an artificial intelligence company that has developed a computational biomarker that has been proven in four years of clinical trials at MIT to substantially change the way disease is managed for a wide range of neuromotor, neurocognitive and neurobehavioral disorders. nQ focuses on analysis of user interaction with common electronic devices to capture functional decline related to neurodegenerative disorders. The fine control of typing and touch screen kinematics together with the frequent use of electronic devices allows for precise monitoring of small changes in neurodegeneration that frequently go unnoticed by clinicians.

### CONTACT

Richie Bavasso  
Chief Executive Officer  
McDermott Partner:  
Brian Bunn



Peach IntelliHealth Inc. is a New York based company using artificial intelligence & machine learning (AI/ML) in health care. Its mission is to improve health care outcomes through actionable data analytics. Its proprietary technology is grounded in machine learning and artificial intelligence. Peach IntelliHealth deploys sophisticated modeling of complex data to facilitate understanding of their interdependencies and enable customizable solutions.

#### CONTACT

Klaudyne Hong  
Chief Executive Officer  
McDermott Partner:  
Jed Gordon



Prapela is an infant sleep tech company focused on the integration of stochastic resonance technology into medical and consumer products to help newborns breathe and relax.

#### CONTACT

John Konsin  
Chief Executive Officer and  
Founder  
McDermott Partner:  
Byron S. Kalogerou

## GRADUATES



Akrivis Technologies, LLC, is a privately held biopharmaceutical company founded in 2009 and headquartered in Cambridge, MA. Akrivis is engaged in the early diagnosis and treatment of serious and life-threatening diseases. Akrivis' main asset is its proprietary Z-TECT™ technology platform that provides ultrasensitive detection and accurate quantification of biomolecules present down to the zeptomole range (10E-21 moles). In addition to supporting in vitro and in vivo diagnostic applications, Z-TECT™ will also serve as a novel platform for the targeted delivery of high payloads of radio- and chemotherapeutic drugs for cancer therapy. Potentially providing far safer and more efficacious targeted delivery therapeutics, Z-TECT™ will have a major impact on the emerging field of "Theranostics" that combines cancer therapies with companion in vivo imaging. Learn more at [www.akrivis.com](http://www.akrivis.com).

#### CONTACT

Joel Berniac  
CEO & Co-Founder  
+1 617 955 7725  
McDermott Partner:  
Sarah Hogan



#### Applied Therapeutics Inc.

Applied Therapeutics is a privately held biotechnology company, focused on developing transformative drugs in areas of high unmet medical need—fatal or debilitating diseases for which no therapies are approved. The company applies cutting-edge technology to validated drug targets that have failed to produce meaningful therapies in the past. Applied Therapeutics believes that through innovative science, millions of lives can be saved. For more information, visit [www.appliedtherapeutics.com](http://www.appliedtherapeutics.com).

#### CONTACT

Shoshana Shendelman,  
PhD  
Chief Executive Officer  
+1 646 263 8662



BIOMODEX is a French Medtech company that helps surgeons to validate their medical devices for patient-specific treatments resulting in more predictable and consistent clinical outcomes. The company is developing advanced 3D modeling and 3D printing to fabricate lifelike artificial organs for medical training and pre-operative planning in the clinical and surgical settings. Learn more at [www.biomodex.com](http://www.biomodex.com).

#### CONTACT

Thomas Marchand  
CEO  
McDermott Partner:  
Richard B. Smith



Candesant Biomedical is a medical device company with a platform technology that uses a metal alloy to produce targeted ablation. The technology has many potential applications; the first is a disease responsive device that selectively targets the glands and ducts that produce sweat. This product will address the large and underserved sweat control market. The company has completed preclinical studies to demonstrate the targeted nature of the technology and human proof of concept on subjects who experience exercised-induced sweat. Based in Northern California, the company is founded by industry veterans who have developed and launched products across a number of verticals and have deep expertise in the dermatology and aesthetic markets.

#### CONTACT

Niquette L. Hunt  
President & Chief Executive Officer  
+1 415 726 4888  
McDermott Partner:  
Judy Mohr



Cellaria BioSciences is developing cell culture methods that enable tumor cells taken from a human tumor biopsy to be cultured in such a way that they largely retain the genotypic, proteomic and phenotypic profile of their parent tumor cell type, thus providing a method of generating cells with key utilities for cancer drug discovery and development. In addition to this technology, Cellaria acquired the WIT Media Product line from Stemgent, which expands its media line with a complementary product for normal mammary epithelial cells. Cellaria also has acquired the embryonic stem cell chimera IP from Aveo Pharmaceutical. The IP and associated materials allow us to offer services associated with drug screening for immunotherapy, and develop innovative mouse models that can be marketed through strategic alliances with existing mouse model providers. Learn more at [www.cellariabio.com](http://www.cellariabio.com).

#### CONTACT

David Deems  
Chief Executive Officer  
+1 617 949 2588  
McDermott Partner:  
Richard B. Smith



#### CytoSite Biopharma Inc.

CytoSite Biopharma Inc. is a biotechnology startup developing a new technology to predict and monitor response to immuno-oncology therapy. The company is developing a novel and proprietary small molecule PET imaging probe that will enable clinicians to predict early in the treatment cycle which patients will respond to I-O therapy. The technology upon which CytoSite is based was discovered by co-founders in the laboratory of Umar Mahmood MD PhD, Director of the Center for Precision Imaging at the Martinos Center for Biomedical Imaging, Vice-Chair Radiology at Massachusetts General Hospital, and Professor of Radiology, Harvard Medical School.

#### CONTACT

Jim Jenson, PhD.  
CEO and Co-Founder  
McDermott Partner:  
Richard B. Smith



#### Engine Biosciences

Engine Biosciences' artificial intelligence and genetic perturbation platform allows researchers and drug developers to uncover the gene interactions and biological networks underlying diseases faster and more cost-effectively than conventionally, test therapies that specifically target these interactions, and make important analyses and predictions for precision medicine applications.

#### CONTACT

Timothy Lu, MD  
Co-Founder and Board Member  
McDermott Partner:  
Joanna Lin



Implicity is a medical device software company that provides a cloud platform for remote monitoring of patients implanted with connected medical devices (pacemakers/defibrillators). Artificial intelligence and integration with the electronic health record enable health professionals to follow patients and make faster and more accurate decisions. Using Implicity allows them to deliver remote monitoring to all patients implanted with reduced resources and better quality. Implicity is growing to be the leading solution in Europe in the field of cardiac connected devices.

#### CONTACT

Arnaud Rosier  
Chief Executive Officer & Founder  
McDermott Partner:  
Jennifer Bock

#### Jace Biomedical, Inc.

Jace Biomedical, Inc., is a clinical stage pharmaceutical company developing small molecules with a unique mechanism of action for the treatment of Alzheimer's disease that targets ER protein processing and pathways. Established in 2014, Jace Biomedical entered into a technology option agreement with University of Wisconsin's research foundation, WARF, and holds the option to license IP related to the inhibition/moderation of the BACE1 enzyme which will in turn moderate the amount of Beta-Amyloid in the brain. The technology provides more targeted moderation in early (presymptomatic) patients to dramatically slow the onset of the disease. Learn more at [www.jacebio.com](http://www.jacebio.com).

#### CONTACT

Carl Horn  
Founder & Chief Executive Officer  
McDermott Partner:  
Kristian A. Werling



LipoMedix is a new development-stage privately held company focused on developing Promitil®—Pegylated Liposomal Mitomycin-C Prodrug (PL-MLP)—an innovative agent for targeted cancer therapy. The company was established in order to advance the pharmaceutical and clinical development of a patented prodrug of mitomycin-C and its efficient delivery in liposomes to cancer-affected target organs. This formulation known as Promitil® overcomes the problems associated with mitomycin-C toxicity and turn it into a state-of-the-art anti-cancer drug that will potentially become the therapy of choice in a variety of cancers, especially those derived from the gastrointestinal tract (stomach, pancreas, colorectal). The inventor and scientific founder of LipoMedix is Prof. Alberto Gabizon of the Hebrew University – Shaare Zedek Medical Center who is also the co-inventor and co-developer of Doxil® (the first FDA-approved nano-drug in cancer therapy). Promitil® is an innovative chemotherapeutic agent with distinct advantages over conventional anticancer agents that have adverse side effects and fail to be effective after a relatively short period of time. The technology will enable cancer patients to receive safer therapy with a more potent anti-tumor effect. Learn more at [www.lipomedix.com](http://www.lipomedix.com).

#### CONTACT

Alberto Gabizon  
Chief Executive Officer  
McDermott Partner:  
Judy Mohr



Nemucore Medical Innovations, Inc., is a clinical development company dedicated to the development and commercialization of life-saving molecularly targeted therapeutics for the treatment of multi-drug-resistant cancers with a special emphasis on women's oncology. We accomplish this by partnering with the biomedical leaders in the research and clinical communities to investigate if our proprietary products can be life saving for patients with hard-to-treat oncology indications like ovarian cancer. Learn more at [www.nemucore.com](http://www.nemucore.com).

#### CONTACT


Timothy P. Coleman  
Chief Executive Officer  
& President  
McDermott Partner:  
Byron S. Kalogerou

## POP BIOTECH

Pop biotechnologies, a Buffalo, NY-based, life sciences company dedicated to the development of targeted nanoparticle-based light therapies for diseases for which there are currently no effective treatments or for which current treatments do not perform ideally for patients. Pop biotechnologies' goal is to produce effective treatments that specifically target disease, reduce treatment side-effects and improve patient outcomes. Pop biotechnologies' proprietary porphyrin-phospholipid liposome technology (nanopop) is a platform for creating targeted therapeutics. Nanopops have the ability to take on specific properties depending on the amount of the lipid used and the variation. The first variation nanopop is formulated to be responsive to light in a way that causes it to release encapsulated payloads. Learn more at [www.popbiotechnologies.com](http://www.popbiotechnologies.com).

#### CONTACT

Jonathan Smyth  
Co-founder  
+1 315 220 0087  
McDermott Partner:  
Sarah Hogan



#### Protein Dynamic Solutions (PDS)

Protein Dynamic Solutions provides state-of-the-art protein characterization to ensure viability and stability of protein products for the biopharma and biotechnology industry. PDS focuses on the only bioanalytical method to determine the size and identity of the aggregate, mechanism of protein aggregation, extent of aggregation and the stability of the protein therapeutic, as well as on intellectual property development.

#### CONTACT

Dr. Belinda Pastrana  
Chief Executive Officer  
+1 787 485 6932



Vasoptic Medical, Inc. is an early-stage medical device company with a mission to advance health care through innovation in medical diagnostics. The company's technology will be used for the rapid and inexpensive assessment of the functional state of the retina, which can lead to timely detection of information pertaining to health and disease conditions. Vasoptic's initial focus is enabling primary care providers and health care retailers to perform routine eye exams in their diabetic patient population for early detection of diabetic retinopathy.

#### CONTACT

M. Jason Brooke, MSE,  
JD  
Chief Executive Officer  
+1 202 258 1422  
McDermott Partner:  
Jason B. Caron

McDermott  
Will & Emery

[mwe.com](http://mwe.com) | [f](#) [in](#) [t](#)